1. BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
- Author
-
Mar Orzáez and Mónica Sancho
- Subjects
0301 basic medicine ,Cancer Research ,Programmed cell death ,Myeloid ,Cell ,BCL-2 ,Apoptosis ,Biology ,03 medical and health sciences ,BOK ,0302 clinical medicine ,medicine ,Author’s Views ,MCL1 ,transmembrane domain ,medicine.disease ,Transmembrane protein ,Transmembrane domain ,Leukemia ,030104 developmental biology ,medicine.anatomical_structure ,Cancer research ,Molecular Medicine ,030217 neurology & neurosurgery ,Article Commentary - Abstract
Myeloid cell leukemia 1 (MCL1) gene amplification occurs in a wide range of human cancers and protein overexpression associates with malignant cell growth and evasion of apoptosis. We recently reported that disrupting the interaction between the transmembrane domains of MCL1 and BCL-2 related ovarian killer (BOK) induces cell death, thereby suggesting a new target site for anti-tumorigenic strategies.
- Published
- 2021